Nektar Therapeutics (NKTR)Healthcare | Biotechnology | San Francisco, United States | NasdaqCM
84.86 USD
+0.87
(1.036%)
⇧
(April 17, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 19, 2026, 12:53 a.m. EDT
The stock is trading as a 'make-or-break' binary playsight on their REZPEG data, supported by aggressive call positioning at 100-110 strikes. However, the deteriorating fundamentals (-25% revenue growth, negative earnings, high debt/equity) and the presence of active litigation class action deadlinewith 26 suggest a high risk of value destruction. The bullish IV spikes at deep OTM levels are a contrarian signal that speculators fear a catalyst failure as much as they hope for a moonshot success. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.517813 |
| AutoETS | 0.521947 |
| AutoTheta | 0.657326 |
| AutoARIMA | 0.790572 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 5.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.008 |
| Excess Kurtosis | -0.68 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 165.763 |
| Revenue per Share | 3.274 |
| Market Cap | 2,434,460,672 |
| Forward P/E | -7.55 |
| Beta | 1.18 |
| Profit Margins | -297.07% |
| Website | https://www.nektar.com |
As of April 19, 2026, 12:53 a.m. EDT: Options flow is dominated by long calls at high strikes (100-110) by August/Nov 2026, while short-to-mid-term expiries show heavy put options (OTM) on declines, likely hedging a specific catalyst or earnings date. However, the IV profile is notably distorted with spikes at deeply OTM strikes (e.g., 43-strike puts), suggesting intelligence-betting on extreme downside fear or a binary event like a litigation verdict or drug rejection. The 1.9x average volume relative to OI on 100-strike calls indicates active speculation on upside momentum driven by recent positive trial data.
| Attribute | Value |
|---|---|
| 52 Week Change | 7.9798946 |
| Address1 | 455 Mission Bay Boulevard South |
| All Time High | 1,670.4 |
| All Time Low | 6.15 |
| Ask | 96.78 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 570,950 |
| Average Daily Volume3 Month | 1,099,013 |
| Average Volume | 1,099,013 |
| Average Volume10Days | 570,950 |
| Beta | 1.176 |
| Bid | 72.24 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 4.408 |
| City | San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 84.86 |
| Current Ratio | 4.974 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 86.95 |
| Day Low | 84.15 |
| Debt To Equity | 165.763 |
| Earnings Call Timestamp End | 1,773,349,200 |
| Earnings Call Timestamp Start | 1,773,349,200 |
| Earnings Timestamp | 1,773,345,600 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -129,745,000 |
| Ebitda Margins | -2.3490899 |
| Enterprise To Ebitda | -18.017 |
| Enterprise To Revenue | 42.324 |
| Enterprise Value | 2,337,616,640 |
| Eps Current Year | -10.0125 |
| Eps Forward | -11.2375 |
| Eps Trailing Twelve Months | -9.73 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 415 339 5300 |
| Fifty Day Average | 70.7208 |
| Fifty Day Average Change | 14.139198 |
| Fifty Day Average Change Percent | 0.19992983 |
| Fifty Two Week Change Percent | 797.98944 |
| Fifty Two Week High | 86.95 |
| Fifty Two Week High Change | -2.0899963 |
| Fifty Two Week High Change Percent | -0.024036761 |
| Fifty Two Week Low | 7.99 |
| Fifty Two Week Low Change | 76.87 |
| Fifty Two Week Low Change Percent | 9.620776 |
| Fifty Two Week Range | 7.99 - 86.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 767,971,800,000 |
| Float Shares | 24,990,371 |
| Forward Eps | -11.2375 |
| Forward P E | -7.5515018 |
| Free Cashflow | -108,228,872 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 63 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 55,232,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00575 |
| Held Percent Institutions | 0.61064 |
| Implied Shares Outstanding | 28,687,963 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.nektar.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,749,427,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California. |
| Long Name | Nektar Therapeutics |
| Market | us_market |
| Market Cap | 2,434,460,672 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_29929 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -164,076,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,434,460,540 |
| Number Of Analyst Opinions | 8 |
| Open | 85.39 |
| Operating Cashflow | -208,511,008 |
| Operating Margins | -0.87541 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.31 |
| Phone | 415 482 5300 |
| Previous Close | 83.99 |
| Price Eps Current Year | -8.475406 |
| Price Hint | 2 |
| Price To Book | 19.251362 |
| Price To Sales Trailing12 Months | 44.076996 |
| Profit Margins | -2.9706697 |
| Quick Ratio | 4.624 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.3 |
| Region | US |
| Regular Market Change | 0.870003 |
| Regular Market Change Percent | 1.03584 |
| Regular Market Day High | 86.95 |
| Regular Market Day Low | 84.15 |
| Regular Market Day Range | 84.15 - 86.95 |
| Regular Market Open | 85.39 |
| Regular Market Previous Close | 83.99 |
| Regular Market Price | 84.86 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 509,820 |
| Return On Assets | -0.27978 |
| Return On Equity | -2.17941 |
| Revenue Growth | -0.253 |
| Revenue Per Share | 3.274 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 28,687,963 |
| Shares Percent Shares Out | 0.1277 |
| Shares Short | 3,663,438 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,342,020 |
| Short Name | Nektar Therapeutics |
| Short Percent Of Float | 0.1293 |
| Short Ratio | 4.32 |
| Source Interval | 15 |
| State | CA |
| Symbol | NKTR |
| Target High Price | 165.0 |
| Target Low Price | 70.0 |
| Target Mean Price | 128.125 |
| Target Median Price | 131.5 |
| Total Cash | 245,752,000 |
| Total Cash Per Share | 8.566 |
| Total Debt | 148,908,000 |
| Total Revenue | 55,232,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -9.73 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 50.4832 |
| Two Hundred Day Average Change | 34.3768 |
| Two Hundred Day Average Change Percent | 0.68095523 |
| Type Disp | Equity |
| Volume | 509,820 |
| Website | https://www.nektar.com |
| Zip | 94,158 |